AFP and Cirrhosis: High-risk population screening: Patients with hepatitis, cirrhosis, and populations in high-incidence areas of liver cancer should regularly monitor alpha-fetoprotein (AFP), abnormal prothrombin (PIVKA-II), and abdominal ultrasound to achieve early diagnosis and treatment.